A Multicenter Randomized, Double-blind, Phase 2, Placebo Controlled Study to Determine the Safety and Efficacy of Ivacaftor (VX-770) for the Treatment of Chronic Obstructive Pulmonary Disease (The Multicenter Topic Trial)
Latest Information Update: 31 Jan 2022
At a glance
- Drugs Ivacaftor (Primary)
- Indications Chronic bronchitis; Chronic obstructive pulmonary disease
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms The Multicenter Topic Trial
Most Recent Events
- 11 Jan 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 27 Apr 2021 Planned initiation date changed from 1 Feb 2021 to 1 Dec 2021.
- 12 Oct 2020 Planned initiation date changed from 1 Sep 2020 to 1 Feb 2021.